Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in treatments for metabolic dysfunction-associated steatohepatitis (MASH), has scheduled its second-quarter 2025 financial results release for August 5, 2025, before U.S. markets open.
The company will host a live webcast at 8:00 AM ET where management will discuss financial and operating results. Participants are advised to register 15 minutes before the webcast, which will be accessible through Madrigal's Investor Relations website. A replay will be available approximately two hours after the live event.
Madrigal Pharmaceuticals (NASDAQ:MDGL), un'azienda biofarmaceutica specializzata in trattamenti per la steatoepatite associata a disfunzioni metaboliche (MASH), ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per il 5 agosto 2025, prima dell'apertura dei mercati statunitensi.
L'azienda terrà una webcast in diretta alle 8:00 AM ET durante la quale il management discuterà i risultati finanziari e operativi. Si consiglia ai partecipanti di registrarsi 15 minuti prima della diretta, che sarà accessibile tramite il sito web delle Relazioni con gli Investitori di Madrigal. Una registrazione sarà disponibile circa due ore dopo l'evento live.
Madrigal Pharmaceuticals (NASDAQ:MDGL), una compañía biofarmacéutica especializada en tratamientos para la esteatohepatitis asociada a disfunción metabólica (MASH), ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el 5 de agosto de 2025, antes de la apertura de los mercados estadounidenses.
La compañía realizará una transmisión en vivo a las 8:00 AM ET donde la dirección discutirá los resultados financieros y operativos. Se recomienda a los participantes registrarse 15 minutos antes de la transmisión, la cual estará disponible a través del sitio web de Relaciones con Inversionistas de Madrigal. Una repetición estará disponible aproximadamente dos horas después del evento en vivo.
Madrigal Pharmaceuticals (NASDAQ:MDGL)는 대사 기능 장애 관련 지방간염(MASH) 치료를 전문으로 하는 바이오제약 회사로, 2025년 8월 5일 미국 시장 개장 전에 2025년 2분기 재무 실적 발표를 예정하고 있습니다.
회사는 동부 표준시 기준 오전 8시에 라이브 웹캐스트를 진행하며, 경영진이 재무 및 운영 결과를 논의할 예정입니다. 참가자는 웹캐스트 시작 15분 전에 등록할 것을 권장하며, Madrigal 투자자 관계 웹사이트를 통해 접속할 수 있습니다. 라이브 이벤트 약 2시간 후에 다시보기 서비스가 제공됩니다.
Madrigal Pharmaceuticals (NASDAQ:MDGL), une société biopharmaceutique spécialisée dans les traitements de la stéatohépatite associée à une dysfonction métabolique (MASH), a programmé la publication de ses résultats financiers du deuxième trimestre 2025 pour le 5 août 2025, avant l'ouverture des marchés américains.
La société organisera une webdiffusion en direct à 8h00 ET au cours de laquelle la direction présentera les résultats financiers et opérationnels. Il est conseillé aux participants de s'inscrire 15 minutes avant la diffusion, accessible via le site des Relations Investisseurs de Madrigal. Une rediffusion sera disponible environ deux heures après l'événement en direct.
Madrigal Pharmaceuticals (NASDAQ:MDGL), ein biopharmazeutisches Unternehmen, das sich auf Behandlungen der metabolisch bedingten Steatohepatitis (MASH) spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 5. August 2025 geplant, und zwar vor Öffnung der US-Märkte.
Das Unternehmen wird um 8:00 Uhr ET ein Live-Webcast veranstalten, in dem das Management die finanziellen und operativen Ergebnisse besprechen wird. Teilnehmer werden gebeten, sich 15 Minuten vor Beginn des Webcasts zu registrieren, der über die Investor-Relations-Website von Madrigal zugänglich sein wird. Eine Aufzeichnung wird etwa zwei Stunden nach der Live-Veranstaltung verfügbar sein.
- None.
- None.
CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its second-quarter 2025 financial results on Wednesday, Aug. 5, 2025, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m.
Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
When will Madrigal Pharmaceuticals (MDGL) release Q2 2025 earnings?
What time is Madrigal Pharmaceuticals' Q2 2025 earnings call?
How can I access Madrigal Pharmaceuticals' Q2 2025 earnings webcast?
What does Madrigal Pharmaceuticals (MDGL) specialize in?
